Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective and Observational Study for Effectiveness and Safety Evaluation of VedAryo® (Vedolizumab) in Patients With Inflammatory Bowel Disease

NCT07273760 is registered in ClinicalTrials.gov with AryoGen Pharmed Co. as lead sponsor.

NCT NCT07273760
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07273760 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective and Observational Study for Effectiveness and Safety Evaluation of VedAryo® (Vedolizumab) in Patients With Inflammatory Bowel Disease
Lead sponsor
AryoGen Pharmed Co.
Phase
Observational
Overall status
Completed
Start date
July 16, 2023
Completion date
October 5, 2025
Enrollment
150 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease (cd), inflammatory bowel disease (ibd), ulcerative colitis (uc)